Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21403201 | 0.85 | PDCD1 (0.36) | NPC1RAB9AALDH1A1SMN1; SMN2PDCD1 | |
| SCHEMBL20203398 | 0.85 | PDCD1 (0.36) | NPC1RAB9AALDH1A1SMN1; SMN2PDCD1 | |
| SCHEMBL20037707 | 0.84 | NPSR1 (0.35) | NPC1RAB9AALDH1A1SMN1; SMN2PDCD1 | |
| SCHEMBL26180774 | 0.83 | PKM (0.36) | NPC1RAB9AALDH1A1SMN1; SMN2PDCD1 | |
| SCHEMBL20203415 | 0.83 | LMNA (0.33) | NPC1RAB9ATP53TSHRLMNA | |
| SCHEMBL21403227 | 0.81 | AKT1 (0.34) | NPC1RAB9AALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL20203512 | 0.81 | AKT1 (0.34) | NPC1RAB9AALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL20203508 | 0.78 | CYP2C9 (0.36) | NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL23733435 | 0.78 | MEN1 (0.35) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL20238462 | 0.70 | TP53 (0.34) | NPC1RAB9AALDH1A1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | NPC1 3303/4885RAB9A 2243/4885ALDH1A1 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.